Navigation Links
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSK
Date:7/28/2009

COPENHAGEN, Denmark, July 28 /PRNewswire/ -- Nuevolution today announced the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline.

The agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads. These technologies were developed by Nuevolution and Praecis Pharmaceuticals, a wholly owned subsidiary of GlaxoSmithKline.

Under the terms of the cross-licensing agreement, GlaxoSmithKline will obtain a non-exclusive license under technology patents of Nuevolution, and Nuevolution will obtain a one time license fee and a non-exclusive license under technology patents of GlaxoSmithKline.

Further details of the agreement are not disclosed.

"By entering into this agreement, both companies are offered an optimal basis for continued development and application of the technologies" said Allen Oliff, SVP Molecular Discovery Research of GSK and Alex Gouliaev, CEO of Nuevolution A/S continued "our innovative technologies allow small molecule hit and lead discovery at an unprecedented scale. This agreement secures both companies the rights to operate these powerful technologies to their fullest extent".

About Nuevolution

Nuevolution is a leading lead discovery company founded in 2001 and based in Copenhagen, Denmark. The company has developed Chemetics(R), a unique, patent protected hybrid of proven wet chemistry and molecular biology which represents the ultimate fragment based lead discovery technology. Chemetics(R) enables rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and the efficient screening of these, facilitating the identification of potent drug leads at unprecedented quantity, quality and speed compared to existing lead discovery technologies.

Nuevolution partners its technology with pharmaceutical and biotechnology companies, and is also developing an internal pipeline by applying Chemetics(R) to validated cancer and cardiovascular targets. Nuevolution has demonstrated the power of Chemetics(R) by identifying highly potent and drug like novel ligands with the potential to address major unmet medical needs across a range of therapeutic areas and target classes.

Nuevolution is a privately owned company and has raised EUR 37 million in financing from key Scandinavian investors, including SEB Venture, Sunstone Capital, SLS Invest and Novo A/S. For more information about Nuevolution A/S, please visit the company's website http://www.nuevolution.com

    For further information please contact:

    Nuevolution A/S
    Alex Haahr Gouliaev, CEO
    T: +45-70-20-09-87
    ahg@nuevolution.com



'/>"/>
SOURCE Nuevolution A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nuevolution Announces Progress in Its Collaboration With Merck & Co. Inc.
2. Nuevolution Announces Research and Development Collaboration with Merck & Co. Inc.
3. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
4. SEQUENOM Announces Launch of MassARRAY Compact 96 System
5. Human Genome Sciences Announces Proposed Public Offering of Common Stock
6. Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results
7. Sechrist Industries, World Leader in Hyperbaric Chambers, Announces Edward Pulwer as President/CEO
8. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
9. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
10. Spectrum Announces Fetal Bovine Serum Product Line
11. Cell Therapeutics, Inc. Announces Exercise of Overallotment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Energetiq ... has announced a facility expansion to accommodate its rapid growth. , The renovations ... workspace and renovation of the existing areas. The expansion includes, a state-of-the-art engineering ...
(Date:5/22/2017)... ... 2017 , ... Stratevi, a boutique firm that partners with healthcare companies to ... an office in downtown Boston at 745 Atlantic Ave. , “We are seeing ... evidence on the value they provide, not just to patients, but also payers. Having ...
(Date:5/19/2017)... York (PRWEB) , ... May 19, 2017 , ... In ... in treating gait disorders, Biodex Medical Systems, Inc. announces the release of their Gait ... therapy has been joined with a biomedical system to aid in rehabilitating individuals with ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl ... CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal ... at Eurofins and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior ...
Breaking Biology Technology:
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
Breaking Biology News(10 mins):